Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
| Autor: | Kearsley-Fleet, Lianne, Beresford, Michael W, Davies, Rebecca, De Cock, Diederik, Baildam, Eileen, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L, Dis, Biologics Children Rheumatic |
|---|---|
| Přispěvatelé: | Public Health Sciences |
| Rok vydání: | 2018 |
| Předmět: |
Male
Time Factors Epidemiology Arthritis Antirheumatic Agents/therapeutic use Outcome measures Severity of Illness Index Biologic Therapies chemistry.chemical_compound 0302 clinical medicine Pharmacology (medical) Arthritis Juvenile/drug therapy 030212 general & internal medicine Child skin and connective tissue diseases Statistics Induction Chemotherapy Clinical Science Treatment Outcome Antibodies Monoclonal Humanized/therapeutic use statistics Antirheumatic Agents Child Preschool Cohort epidemiology Female Biological Products/therapeutic use medicine.drug musculoskeletal diseases medicine.medical_specialty Antibodies Monoclonal Humanized Interleukin 1 Receptor Antagonist Protein/therapeutic use outcome measures 03 medical and health sciences Tocilizumab Rheumatology biologic therapies Internal medicine Severity of illness medicine Humans Juvenile Idiopathic Arthritis JIA 030203 arthritis & rheumatology Biological Products Anakinra business.industry Induction chemotherapy medicine.disease Arthritis Juvenile Interleukin 1 Receptor Antagonist Protein Logistic Models chemistry Macrophage activation syndrome business |
| Zdroj: | Rheumatology (Oxford, England) RHEUMATOLOGY Kearsley-Fleet, L, Beresford, M W, Davies, R, De Cock, D, Baildam, E, Foster, H E, Southwood, T R, Thomson, W, Hyrich, K L & Biologics for Children with Rheumatic Diseases Study (BCRD) 2019, ' Short-Term Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis Treated with either Tocilizumab or Anakinra ', Rheumatology (Oxford), vol. 58, no. 1, pp. 94-102 . https://doi.org/10.1093/rheumatology/key262 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/key262 |
| Popis: | Objectives To investigate real-world short-term outcomes among patients with systemic JIA starting tocilizumab or anakinra. Methods This analysis included all systemic JIA patients within the UK Biologics for Children with Rheumatic Diseases study starting tocilizumab or anakinra between 2010 and 2016. Disease activity was assessed at baseline and one year. At one year the following outcomes were assessed: minimal disease activity, clinically inactive disease, 90% ACR Paediatric response (ACRPedi90). Univariable logistic regression was used to identify baseline characteristics associated with these outcomes. Multiple imputation was used to account for missing data. Results Seventy-six systemic JIA patients were included (54 tocilizumab; 22 anakinra). More patients starting anakinra as their first biologic compared with tocilizumab (86% vs 63%; P = 0.04), with shorter disease duration (1 vs 2 years; P = 0.003) and higher frequency of prior macrophage activation syndrome (37% vs 8%; P = 0.004). Overall, at one year, 42% achieved ACRPedi90, 51% minimal disease activity, and 39% clinically inactive disease, with similar responses seen between the two drugs. Response was not associated with baseline disease characteristics. Fifteen (20%) patients stopped biologic treatment by one year. Treatment survival was better with tocilizumab (89% at one year vs 59% anakinra; P = 0.002), with three stopping for anakinra injection-related problems. Conclusion In this real-world cohort of patients with systemic JIA receiving tocilizumab or anakinra, approximately half achieved a minimal disease state by one year. Treatment responses appeared similar between the two therapies albeit with better persistence observed with tocilizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|